Switch theme
Sign up to access all valuation multiples
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
1994
7
LTM Revenue $5.4M
Last FY EBITDA -$14.4M
$82.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Quantum BioPharma has a last 12-month revenue (LTM) of $5.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Quantum BioPharma achieved revenue of n/a and an EBITDA of -$14.4M.
Quantum BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Quantum BioPharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$14.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$9.4M | XXX | -$15.9M | XXX | XXX | XXX |
| EBIT Margin | -173% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$11.9M | XXX | -$14.2M | XXX | XXX | XXX |
| Net Margin | -219% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Quantum BioPharma's stock price is $21.
Quantum BioPharma has current market cap of $81.8M, and EV of $82.6M.
See Quantum BioPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $82.6M | $81.8M | XXX | XXX | XXX | XXX | $-7.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Quantum BioPharma has market cap of $81.8M and EV of $82.6M.
Quantum BioPharma's trades at n/a EV/Revenue multiple, and -5.7x EV/EBITDA.
Equity research analysts estimate Quantum BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Quantum BioPharma has a P/E ratio of -6.9x.
See valuation multiples for Quantum BioPharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $81.8M | XXX | $81.8M | XXX | XXX | XXX |
| EV (current) | $82.6M | XXX | $82.6M | XXX | XXX | XXX |
| EV/Revenue | 15.2x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -5.7x | XXX | XXX | XXX |
| EV/EBIT | -8.8x | XXX | -5.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.9x | XXX | -5.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQuantum BioPharma's last 12 month revenue growth is 132%
Quantum BioPharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.3M for the same period.
Quantum BioPharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Quantum BioPharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Quantum BioPharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 132% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Quantum BioPharma acquired XXX companies to date.
Last acquisition by Quantum BioPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Quantum BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Quantum BioPharma founded? | Quantum BioPharma was founded in 1994. |
| Where is Quantum BioPharma headquartered? | Quantum BioPharma is headquartered in United States of America. |
| How many employees does Quantum BioPharma have? | As of today, Quantum BioPharma has 7 employees. |
| Who is the CEO of Quantum BioPharma? | Quantum BioPharma's CEO is Mr. Zeeshan Saeed. |
| Is Quantum BioPharma publicy listed? | Yes, Quantum BioPharma is a public company listed on NAS. |
| What is the stock symbol of Quantum BioPharma? | Quantum BioPharma trades under QNTM ticker. |
| When did Quantum BioPharma go public? | Quantum BioPharma went public in 2018. |
| Who are competitors of Quantum BioPharma? | Similar companies to Quantum BioPharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Quantum BioPharma? | Quantum BioPharma's current market cap is $81.8M |
| What is the current revenue of Quantum BioPharma? | Quantum BioPharma's last 12 months revenue is $5.4M. |
| What is the current revenue growth of Quantum BioPharma? | Quantum BioPharma revenue growth (NTM/LTM) is 132%. |
| What is the current EV/Revenue multiple of Quantum BioPharma? | Current revenue multiple of Quantum BioPharma is 15.2x. |
| Is Quantum BioPharma profitable? | Yes, Quantum BioPharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
